Breast cancer-related preferences among women with and without BRCA mutations

Breast Cancer Research and Treatment

Volumn 119, Issue 1, 2010, Pages 177-184

  Grann, Victor R ^a   Patel, Priya ^b   Bharthuar, Anubha ^c   Jacobson, Judith S ^d   Warner, Ellen ^e   Anderson, Kristin ^f   Warner, Eiran ^g   Tsai, Wei Yann ^a   Hill, Kimberly A ^e   Neugut, Alfred I ^a   Hershman, Dawn ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d University of Toronto ^*  (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

BRCA1 2 mutations; Cost effectiveness; MRI and prophylactic surgery; Preferences; Quality adjusted life years

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER SCREENING; CAUCASIAN; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEALTH CARE POLICY; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; SALPINGOOOPHORECTOMY;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MEDICAL ONCOLOGY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; QUALITY OF LIFE;

EID: 72449128147     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0373-6     Document Type: Article

References (28)

1. Y Miki J Swensen D Shattuck-Eidens, et al. 1994 A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 5182 66 71 10.1126/science.7545954 10.1126/science.7545954 1:CAS:528:DyaK2MXhtF2ns70%3D 7545954 (Pubitemid 24345325)
2. R Wooster G Bignell J Lancaster, et al. 1995 Identification of the breast cancer susceptibility gene BRCA2 Nature 378 6559 789 792 10.1038/378789a0 10.1038/378789a0 1:CAS:528:DyaK28XltFWi 8524414 (Pubitemid 26004412)
3. VR Grann JS Jacobson D Thomason D Hershman DF Heitjan AI Neugut 2002 Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis J Clin Oncol 20 10 2520 2529 10.1200/JCO.2002.10.101 10.1200/JCO.2002.10.101 12011131 (Pubitemid 34525739)
4. ND Kauff 2008 Is it time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer? J Clin Oncol 26 1 9 10 10.1200/JCO.2007.14.0244 10.1200/JCO.2007.14.0244 18165631
5. E Warner DB Plewes KA Hill, et al. 2004 Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination JAMA 292 11 1317 1325 10.1001/jama.292.11.1317 10.1001/jama.292.11.1317 1:CAS:528:DC%2BD2cXns12rs78%3D 15367553 (Pubitemid 39223222)
6. K Anderson JS Jacobson DF Heitjan, et al. 2006 Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation Ann Intern Med 144 6 397 406 16549852
7. R Calderon-Margalit O Paltiel 2004 Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature Int J Cancer 112 3 357 364 10.1002/ijc.20429 10.1002/ijc.20429 1:CAS:528: DC%2BD2cXovVelsr8%3D 15382059 (Pubitemid 39390598)
8. M Cappelli L Surh L Humphreys, et al. 2001 Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing Qual Life Res 10 7 595 607 10.1023/A:1013123915272 10.1023/A:1013123915272 1:STN:280: DC%2BD38%2FptlyhtQ%3D%3D 11822793 (Pubitemid 34056330)
9. LJ Fallowfield 2004 Evolution of breast cancer treatments: current options and quality-of-life considerations Eur J Oncol Nurs 8 Suppl 2 S75 S82 10.1016/j.ejon.2004.09.005 10.1016/j.ejon.2004.09.005 15590318
10. C Lindley JS McCune TE Thomason, et al. 1999 Perception of chemotherapy side effects cancer versus noncancer patients Cancer Pract 7 2 59 65 10.1046/j.1523-5394.1999.07205.x 10.1046/j.1523-5394.1999.07205.x 1:STN:280:DyaK1M3otVCjuw%3D%3D 10352062 (Pubitemid 29148608)
11. R Steinbrook 2008 Saying no isn't NICE-The travails of Britain's National Institute for Health and Clinical Excellence N Engl J Med 359 19 1977 1980 10.1056/NEJMp0806862 10.1056/NEJMp0806862 1:CAS:528:DC%2BD1cXhtleju7rI 18987366
12. GW Torrance 1987 Utility approach to measuring health-related quality of life J Chronic Dis 40 6 593 603 10.1016/0021-9681(87)90019-1 10.1016/0021-9681(87)90019-1 1:STN:280:DyaL2s3ltFWlsA%3D%3D 3298297 (Pubitemid 17084806)
13. RM Kaplan 2003 The significance of quality of life in health care Qual Life Res 12 suppl 1 3 16 10.1023/A:1023547632545 10.1023/A:1023547632545 12803306 (Pubitemid 36609835)
14. CM McDonough AN Tosteson 2007 Measuring preferences for cost-utility analysis: how choice of method may influence decision-making Pharmacoeconomics 25 2 93 106 10.2165/00019053-200725020-00003 10.2165/00019053-200725020-00003 17249853 (Pubitemid 46175547)
15. GW Torrance 2006 Utility measurement in healthcare: the things I never got to Pharmacoeconomics 24 11 1069 1078 10.2165/00019053-200624110-00004 10.2165/00019053-200624110-00004 17067192
16. Gold M, Siegel J, Russell L, Weinstein M (eds) (1996) Cost-effectiveness in health and medicine New York. Oxford University Press, New York
17. ML Slevin L Stubbs HJ Plant, et al. 1990 Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public BMJ 300 6737 1458 1460 10.1136/bmj.300.6737.1458 1:STN:280:DyaK3czjsFGjtg%3D%3D 2379006
18. AM Stiggelbout E de Vogel-Voogt 2008 Health state utilities: a framework for studying the gap between the imagined and the real Value Health 11 1 76 87 18237362
19. MS van Roosmalen PF Stalmeier LC Verhoef, et al. 2004 Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation Br J Cancer 90 2 333 342 10.1038/sj.bjc.6601525 10.1038/sj.bjc.6601525 14735173 (Pubitemid 38250625)
20. GW Torrance D Feeny 1989 Utilities and quality-adjusted life years Int J Technol Assess Health Care 5 4 559 575 10.1017/S0266462300008461 1:STN:280:DyaK3c3js1Kitg%3D%3D 2634630
21. VR Grann JS Jacobson V Sundararajan, et al. 1999 The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations Cancer J Sci Am 5 5 283 292 1:STN:280:DyaK1MvlsFGruw%3D%3D 10526669
22. SK Plevritis AW Kurian BM Sigal, et al. 2006 Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging JAMA 295 20 2374 2384 10.1001/jama.295.20.2374 10.1001/jama.295.20.2374 1:CAS:528:DC%2BD28Xlt1WksL8%3D 16720823 (Pubitemid 43788105)
23. MS van Roosmalen LC Verhoef PF Stalmeier 2002 Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy J Clin Oncol 20 8 2092 2100 10.1200/JCO.2002.08.035 10.1200/JCO.2002.08.035 11956270 (Pubitemid 34408800)
24. DL Sackett GW Torrance 1978 The utility of different health states as perceived by the general public J Chronic Dis 31 11 697 704 10.1016/0021- 9681(78)90072-3 10.1016/0021-9681(78)90072-3 1:STN:280:DyaE1M%2FovVyltw%3D%3D 730825
25. MB Hatcher L Fallowfield R A'Hern 2001 The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews BMJ 7278 76 10.1136/bmj.322.7278.76 10.1136/bmj.322.7278.76
26. EJ Emanuel VR Fuchs AM Garber 2007 Essential elements of a technology and outcomes assessment initiative JAMA 298 1323 1325 10.1001/jama.298.11.1323 10.1001/jama.298.11.1323 1:CAS:528:DC%2BD2sXhtVygsbzE 17878424 (Pubitemid 47443345)
27. N Kirschner SG Pauker JW Stubbs, et al. 2008 Information on cost-effectiveness: an essential product of a national comparative effectiveness program Ann Intern Med 148 12 956 961
28. LB Russell MR Gold JE Siegel, et al. 1996 The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine JAMA 276 14 1172 1177 10.1001/jama.276.14.1172 10.1001/jama.276.14.1172 1:STN:280:DyaK28visFGrsA%3D%3D 8827972 (Pubitemid 26329746)